Valuation: Gain Therapeutics, Inc.

Market Cap 77.63M 67.15M 62.71M 57.53M 108M 7.39B 110M 736M 289M 3.7B 292M 285M 12.24B P/E 2026 *
-3.26x
P/E 2027 * -2.45x
Enterprise Value 77.63M 67.15M 62.71M 57.53M 108M 7.39B 110M 736M 289M 3.7B 292M 285M 12.24B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.71%
Yield 2026 *
-
Yield 2027 * -
1 day+2.25%
1 week+8.33%
Current month+8.33%
1 month+1.68%
6 months+4.00%
Current year-43.48%
1 week 1.66
Extreme 1.66
1.86
1 month 1.59
Extreme 1.59
1.89
Current year 1.53
Extreme 1.53
3.29
1 year 1.45
Extreme 1.45
4.34
3 years 0.89
Extreme 0.89
5.33
5 years 0.89
Extreme 0.89
9.75
10 years 0.89
Extreme 0.89
17.93
Manager TitleAgeSince
Chief Executive Officer 52 25/06/2024
Director of Finance/CFO 37 06/01/2025
Chief Tech/Sci/R&D Officer - 25/03/2024
Director TitleAgeSince
Chairman 69 01/01/2017
Director/Board Member 63 01/05/2019
Director/Board Member 58 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Free

Director

25,000 0.0586%
15/07/26 Free

Founder

25,000 0.0586%
15/07/26 Free

Director

25,000 0.0586%
Change 5-day change 1-year change 3-year change Capi.($)
+2.25%+8.33%+22.97%-51.21% 77.63M
+0.99%+1.78%+5.07%+16.49% 49.47B
+3.71%+9.40%+486.14%+579.98% 43.97B
+5.60%+10.21%+20.85%+81.78% 39.6B
+2.70%+1.57%+32.71%+9.07% 39.29B
+2.21%+6.75%+20.20%+54.40% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+124.45% 16.49B
-0.11%+2.41%+5.03%+20.47% 14.01B
+0.75%+15.04%+79.84%+29.70% 12.77B
Average +2.13%+6.52%+78.76%+96.13% 26.49B
Weighted average by Cap. +2.54%+6.10%+105.11%+138.61%

Financials

2026 *2027 *
Net sales - -
Net income -24.41M -21.11M -19.71M -18.09M -34.02M -2.32B -34.56M -231M -90.79M -1.16B -91.65M -89.64M -3.85B -36.06M -31.19M -29.13M -26.72M -50.26M -3.43B -51.05M -342M -134M -1.72B -135M -132M -5.69B
Net Debt - -
Logo Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Employees
-
Date Price Change Volume
07/08/26 $1.820 +2.25% 342,932
06/08/26 $1.780 -1.11% 371,942
05/08/26 $1.800 +2.27% 297,495
04/08/26 $1.760 +0.57% 282,566
03/08/26 $1.750 +4.17% 390,863
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.820USD
Average target price
7.200USD
Spread / Average Target
+295.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GANX Stock